1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

Stockwatch: UniQure's guile and the dubious promise of gene therapy

 
• By Andy Smith

After last week's headline-grabbing deal between Bristol Myers Squibb (BMS) and Dutch gene therapy company uniQure (scripintelligence.com, 6 April 2015), who would have thought that events in Europe might by the end of the week spell the demise of uniQure's gene therapy platform?

After last week's headline-grabbing deal between Bristol Myers Squibb (BMS) and Dutch gene therapy company uniQure (scripintelligence.com, 6 April 2015), who would have thought that events in Europe might by the end of the week spell the demise of uniQure's gene therapy platform?

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

Stock Watch: Disappointing ACC Share Price Reactions For AstraZeneca And Lilly

 
• By Andy Smith

The end of the American College of Cardiology conference was a prelude to a volatile trading week for most stocks. Even before Liberation Day, reactions to the conference announcements were not encouraging.

Verve Moves Toward Lilly Opt-In For PCSK9 Program With Phase Ib Results

 
• By Alaric DeArment

The company posted positive initial results from the Heart-2 trial in HeFH and CAD, with strong LDL cholesterol lowering and a clean safety profile.

Boehringer Boss Talks Tariffs And State Of Play In The US

 
• By Kevin Grogan

The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.

Edgewise’s HCM Candidate May Provide Advantages Over BMS’s Camzyos

 
• By Joseph Haas

With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.

More from Therapy Areas

Pfizer’s Danuglipron Is Done, Sparking M&A Speculation

 
• By Jessica Merrill

The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.

Amgen’s Imdelltra Sets The Pace In Small-Cell Lung Cancer

 
• By Andrew McConaghie

The bispecific is the first in its class to record a Phase III survival win in small-cell lung cancer, although antibody-drug conjugates and other rivals could challenge in the coming years.

Scancell Signs UK Match-Making Pact For Melanoma Vaccine

 
• By Kevin Grogan

The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.